Peptídeos, promovidos como antienvelhecimento e para performance, carecem de comprovação científica e aprovação regulatória no Brasil. Especialistas alertam para riscos de uso sem orientação médica.
O reposicionamento de medicamentos, que consiste em encontrar novos usos para fármacos já existentes, tem se mostrado uma estratégia eficaz e econômica para salvar vidas, especialmente em crises de saúde como a da COVID-19. Medicamentos como a dexametasona e o baricitinibe foram reaproveitados para tratar a inflamação em pacientes com coronavírus, salvando milhares de vidas. A Comissão Europeia planeja expandir essa abordagem para a busca de tratamentos contra o câncer. Exemplos históricos incluem o raloxifeno para prevenção de câncer de mama, a talidomida para mieloma múltiplo e o Viagra (sildenafil) para disfunção erétil, originalmente desenvolvido para doenças cardiovasculares. A tendência de reaproveitamento de medicamentos levanta questões sobre seus verdadeiros prós e contras, cujas respostas podem levar anos para serem totalmente compreendidas.
Novas diretrizes médicas nos EUA e Brasil priorizam semaglutida e tirzepatida para obesidade, com foco em mudanças de estilo de vida. Documentos organizam drogas por hierarquia e risco cardiovascular, visando melhorar saúde e reduzir mortalidade.
Des utilisateurs d'Ozempic et d'autres médicaments amaigrissants rapportent une nouvelle obsession pour les parfums gourmands, certains allant jusqu'à les utiliser comme substituts de repas. D'autres se plaignent d'effets secondaires olfactifs moins agréables.
Poolbeg Pharma will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS), a dangerous side-effect of cancer immunotherapy. The drug could improve patient safety and save healthcare systems millions by allowing treatment outside specialist centers.
Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.
The article explores drug repurposing, highlighting GLP-1 agonists like Ozempic and Wegovy, initially for diabetes, now used for weight loss, cardiovascular health, and more. It also discusses COVID-19 treatments like dexamethasone and baricitinib, and historical examples like raloxifene, thalidomide, BCG vaccine, and Viagra, emphasizing both the benefits and potential risks of using drugs for unapproved conditions.
Worldpanel by Numerator araştırması, zayıflama ilaçları kullanan hanelerin market harcamalarında 780 milyon sterlin düşüş yaşandığını ortaya koydu. Kullanıcılar daha az ürün alıp, eskiden sevdikleri yiyeceklerden keyif almadıklarını belirtiyor.
The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
Online telehealth pharmacies are booming, selling GLP-1s and weight-loss drugs. However, many consumers report being charged for unsolicited medications, facing impossible cancellation policies, and experiencing unresponsive customer service, leading to significant financial losses and frustration.
Boehringer Ingelheim's experimental drug, survodutide, has shown significant potential in reducing liver fat accumulation, a condition known as MASLD/MASH. Presented at the American Diabetes Association (ADA) annual meeting, the drug targets both weight loss and metabolic health, offering a new approach beyond traditional obesity treatments.
تشير دراسة أمريكية جديدة إلى أن أدوية إنقاص الوزن الحديثة من فئة GLP-1 قد تقلل خطر الإصابة ببعض أنواع السرطان المرتبطة بالسمنة بنسبة تصل إلى 41%، مع انخفاض ملحوظ لدى الرجال وسرطان بطانة الرحم.
GLP-1 weight-loss drug users in Great Britain are saving an average of £418 annually on groceries, with household use nearly tripling in two years to 1.9 million adults. The drugs are impacting food consumption and forcing retailers to adapt.
Recent studies suggest GLP-1 obesity treatments may reduce cancer risk, showing correlation with decreased incidence in 6 out of 7 cancers, potentially through anti-inflammatory effects beyond weight loss.
Researchers in Beijing have developed a new oral drug, HRS-7535, a GLP-1 receptor agonist, showing significant reductions in HbA1c levels in a Phase 2 trial for type 2 diabetes patients. The drug may offer a simpler alternative to injectable treatments like Ozempic.
Anti-obesity drugs like GLP-1 analogues are altering consumer behavior, affecting sales of snacks, sodas, and meal replacements. Companies like Nestlé and Danone are acquiring meal substitute startups to adapt to these changes.
Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and has already led to price reductions for brand-name medications.
Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and may pressure US prices, though generics are not expected there until 2032.
Dört yeni çalışma, GLP-1 ilaçlarının tümör ilerlemesini yavaşlattığını, ölüm riskini azalttığını ve meme kanseri yakalanma ihtimalini %25 düşürdüğünü gösterdi. Etkinin kilo kaybı veya doğrudan biyolojik müdahale yoluyla olabileceği düşünülüyor.
Исследователи из Университета Пенсильвании обнаружили, что препараты класса GLP-1, используемые для лечения диабета и снижения веса, связаны с 30% снижением риска рака молочной железы у женщин. Результаты представлены на конгрессе ASCO.
A study of nearly 112,000 women found those taking GLP-1 drugs for diabetes or weight loss had a 30% lower chance of developing breast cancer. Researchers suggest metabolic effects and weight reduction may inhibit tumor growth.
Withings launches the BodyFit, a $280 smart scale targeting users of GLP-1 agonists like Ozempic and Wegovy. It offers segmented body composition analysis and ECG, claiming 98% accuracy for muscle mass and 99% for fat mass compared to clinical DEXA scans.
Biomagistral, a Brazilian compounding pharmacy network, is expanding internationally with a model integrating human and veterinary services. The company plans to open branches in Argentina, Spain, and Colombia, leveraging trends in personalized medicine and pet care.
